<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To determine the activity of fenretinide in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, 15 patients were treated (300 mg/d starting dose, escalated to 400 mg/d) for a 12-week course </plain></SENT>
<SENT sid="1" pm="."><plain>No responses were observed in 14 evaluable patients </plain></SENT>
<SENT sid="2" pm="."><plain>Exacerbation of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> occurred in one patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo>, who succumbed to an <z:hpo ids='HP_0001342'>intracerebral hemorrhage</z:hpo> after 3 weeks of treatment </plain></SENT>
<SENT sid="3" pm="."><plain>Two patients with long-standing stable <z:hpo ids='HP_0001924'>sideroblastic anemia</z:hpo> experienced interval leukemic progression </plain></SENT>
<SENT sid="4" pm="."><plain>In one patient, clinical features of <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> appeared, characterized by a striking rise in peripheral monocyte count (0.49 x 10(9)/l to 10.8 x 10(9)/l) and <z:hpo ids='HP_0001433'>hepatosplenomegaly</z:hpo>, which resolved promptly after cessation of treatment </plain></SENT>
<SENT sid="5" pm="."><plain>The second patient experienced evolution into <z:hpo ids='HP_0004820'>acute myelomonocytic leukemia</z:hpo> with cytogenetic progression </plain></SENT>
<SENT sid="6" pm="."><plain>The drug was well tolerated with no patient having to discontinue treatment because of toxicity </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that fenretinide lacks clinical efficacy in the treatment of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> and in some patients may enhance leukemic progression </plain></SENT>
</text></document>